Lisanti Capital Growth LLC Lowers Stock Position in Ionis Pharmaceuticals, Inc. $IONS

Posted by Brian Himes on May 24th, 2026

Lisanti Capital Growth LLC lowered its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 64.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,789 shares of the company’s stock after selling 59,335 shares during the period. Lisanti Capital Growth LLC’s holdings in Ionis Pharmaceuticals were worth $2,594,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Golden State Wealth Management LLC raised its holdings in shares of Ionis Pharmaceuticals by 198.4% in the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock valued at $25,000 after purchasing an additional 250 shares during the last quarter. Quarry LP purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter valued at about $38,000. Johnson Financial Group Inc. purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter valued at about $44,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at about $47,000. Finally, Bayforest Capital Ltd raised its holdings in shares of Ionis Pharmaceuticals by 608.4% in the fourth quarter. Bayforest Capital Ltd now owns 1,091 shares of the company’s stock valued at $86,000 after purchasing an additional 937 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on IONS. Wall Street Zen upgraded shares of Ionis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, May 2nd. Piper Sandler raised their price objective on shares of Ionis Pharmaceuticals from $87.00 to $100.00 and gave the stock an “overweight” rating in a report on Friday, February 27th. Needham & Company LLC raised their price objective on shares of Ionis Pharmaceuticals from $103.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Royal Bank Of Canada raised their price objective on shares of Ionis Pharmaceuticals from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, April 30th. Finally, HC Wainwright raised their price objective on shares of Ionis Pharmaceuticals from $120.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $100.90.

Read Our Latest Analysis on Ionis Pharmaceuticals

Ionis Pharmaceuticals Stock Performance

NASDAQ IONS opened at $75.56 on Friday. Ionis Pharmaceuticals, Inc. has a 52-week low of $32.00 and a 52-week high of $86.74. The company has a 50-day simple moving average of $74.18 and a 200 day simple moving average of $77.58. The company has a debt-to-equity ratio of 2.75, a quick ratio of 4.09 and a current ratio of 4.10. The company has a market capitalization of $12.49 billion, a PE ratio of -36.50 and a beta of 0.38.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.29. The business had revenue of $246.00 million during the quarter, compared to the consensus estimate of $195.57 million. Ionis Pharmaceuticals had a negative net margin of 30.91% and a negative return on equity of 58.65%. The firm’s quarterly revenue was up 86.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.93) earnings per share. On average, research analysts predict that Ionis Pharmaceuticals, Inc. will post -3.76 EPS for the current year.

Insider Transactions at Ionis Pharmaceuticals

In other news, EVP Kyle Jenne sold 37,277 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $75.85, for a total value of $2,827,460.45. Following the completion of the transaction, the executive vice president owned 11,714 shares in the company, valued at $888,506.90. This trade represents a 76.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allene M. Diaz sold 54,878 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $79.35, for a total transaction of $4,354,569.30. Following the completion of the transaction, the director owned 3,811 shares of the company’s stock, valued at $302,402.85. The trade was a 93.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 616,371 shares of company stock valued at $46,406,452. 2.60% of the stock is currently owned by insiders.

Ionis Pharmaceuticals Company Profile

(Free Report)

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.